Slide 1

La gnomique dans lEspace Europen de la Recherche Le 6me programme cadreLe 6me programme cadre Le contexte politique

Slide 2

Slide 3

FP5/QoL : mio 2.2 FP6/TP1+TP5 : mio 3.0 1800 Projects~ 400 TI ~ 200 NI 80% 20% LESS with MORE : less projects, higher focussing but more organisation implied

Slide 4

5th Framework Programme (1998 - 2002) The 6th Framework Programme (2002 - 2006) Quality of Life programme Thematic Priority 1 or 5 Public dialogue Innovation and technology transfer initiatives Innovation and technology transfer initiatives wet science wet science Bioethics Research Bioethics Research Socio-economic research Socio-economic research Ethics Public dialogue Innovation and competitiveness wet science Academia - Industry - Engineering Regulation and governance Fragmentation

Slide 5

Life Sciences, Genomics and Biotechnology for Health (FP6) Life Sciences, Genomics & biotechnology for health Advanced Genomics and its applications for health (1100 M) Fundamental knowledge and basic tools for functional genomics in all organisms (Structural genomics; proteomics; comparative genomics; bioinformatics; Multidisciplinary genomics approaches to basic biological processes) Application of knowledge and technologies in the field of genomics and biotechnology for health (Technology platforms; support to start-up companies) Advanced Genomics and its applications for health (1100 M) Fundamental knowledge and basic tools for functional genomics in all organisms (Structural genomics; proteomics; comparative genomics; bioinformatics; Multidisciplinary genomics approaches to basic biological processes) Application of knowledge and technologies in the field of genomics and biotechnology for health (Technology platforms; support to start-up companies) Combating major diseases (1155 M) Application-oriented approach to medical genomics knowledge (Cardiovascular disease, diabetes and rare diseases ; resistance to antibiotics ; Studying the brain and combating diseases of the nervous system ; Studying human development and the ageing process) Broader biomedical approach (cancer, poverty-related infectious diseases) Combating major diseases (1155 M) Application-oriented approach to medical genomics knowledge (Cardiovascular disease, diabetes and rare diseases ; resistance to antibiotics ; Studying the brain and combating diseases of the nervous system ; Studying human development and the ageing process) Broader biomedical approach (cancer, poverty-related infectious diseases)

Slide 6

Slide 7

Slide 8

Slide 9

Fundamental knowledge and basic tools for functional genomics in all organisms Structural genomics LSH-2003-1.1.2-1: Comparative structural biology of viral replication IP. The focus should be on developing new approaches, tools and technologies for collecting comprehensive structural information on the replicative machinery of RNA viruses to facilitate the identification of potential new drug targets. LSH-2003-1.1.2-2: Structure determination of large protein complexes IP. The focus should be on the high throughput isolation of cellular protein complexes under physiological conditions and their structural analysis. SECOND CALL TOPICS

Slide 10

Fundamental knowledge and basic tools for functional genomics in all organisms Multidisciplinary functional genomics approaches to basic biological processes MITOCHECK (IP) Regulation of mitosis by phosphorylation FUNGENES (IP) Functional genomics in engineered mouse ES cells No project selected LYMPH/ANGIOGENOMICS (IP) Genome wide discovery and functional analysis of novel genes in lymph/angiogenesis FIRST CALL TOPICSPROJECTS FUNDED The cell cycle Non-human embryonic stem cells Erythroid development and disorders Lymph/angiogenesis

Slide 11

Epigenetics Chronic inflammation Ubiquitin-proteasome pathway Fundamental knowledge and basic tools for functional genomics in all organisms Multidisciplinary functional genomics approaches to basic biological processes FIRST CALL TOPICS PROJECTS FUNDED THE EPIGENOME (NoE) Epigenetic plasticity of the genome + The European epigenetics network MAIN (NoE) Targeting cell migration in chronic inflammation No project selected

Slide 12

Fundamental knowledge and basic tools for functional genomics in all organisms Multidisciplinary functional genomics approaches to basic biological processes SECOND CALL TOPICS LSH-2003-1.1.5-1: Functional genomics approaches in animal models to study human kidney disease IP/NOE. The focus should be on integrating different expertise, animal models and functional genomics platforms to discover the genetic mechanisms that underlie kidney development and cause kidney disease. LSH-2003-1.1.5-2: Functional genomics approaches to the study of peroxisomes in health and disease IP/NOE. The focus should be on using functional genomics approaches and cell and animal models to decipher the entire spectrum of biological functions performed by peroxisomes and to evaluate their roles in disease.

Slide 13

LSH-2003-1.1.5-5: DNA damage and repair mechanisms in health and disease IP. The focus should be on using multidisciplinary functional genomics approaches to decipher the core molecular mechanisms of DNA damage and repair. LSH-2003-1.1.5-6: Functional genomics approaches in animal models to study human immunological disease IP/NOE. The focus should be on bringing together different expertise from academic and industrial (including SMEs) laboratories to generate a joint programme of activities that combines research on model organisms and functional genomics to investigate the immune system for elucidating the genetic basis of immunological disease, thereby facilitating the development of new diagnostics and therapeutic tools. Fundamental knowledge and basic tools for functional genomics in all organisms Multidisciplinary functional genomics approaches to basic biological processes SECOND CALL TOPICS

Slide 14

Fundamental knowledge and basic tools for functional genomics in all organisms Multidisciplinary functional genomics for basic mechanisms of: Transcription activation, signal transduction, intracellular communication, non coding genomic information, integration of genes, in silico predicion and simulation of regulatory networks STREPs and CAs 16 STREPs funded Low abundance mRNAs and proteins, role of small RNAs, nanomachines, apoptosis, comparative genomics in protozoa, standardisation, in silico modelling of macromolecules. CA: Structuring mouse genomics and other models, systems biology, model organisms resources, biobanks FIRST CALL TOPICSSECOND CALL TOPICS

Slide 15

Application of knowledge and technologies in the field of genomics and biotechnology for health new, safer and more effective Rational and accelerated development of new, safer and more effective drugs drugs including pharmacogenomics approaches new diagnostics Development of new diagnostics new in-vitro tests Development of new in-vitro tests to replace animal experimentation new preventive and therapeutic tools Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies research in post-genomics Innovative research in post-genomics, which has high potential for application

Slide 16

New drugs (6) Protein-kinases - novel drug targets (IP) Drugs for depression (IP) Replication & integration of HIV (IP) Individualised medicines (missing) Blood substitutes G-protein coupled receptors European Labcourse: gene vectors (SSA) Application of knowledge and technologies in the field of genomics and biotechnology for health Diagnostics (2) Non-invasive advances in prenatal diagnosis (NoE) Molecular diagnostics of kidney disease Diagnostic for prion diseases (missing) In Vitro alternatives (3) Hazard and risk assessment of reproductive toxicity (IP) In vitro assays for long term toxicity Alternative methods (SSA) New Therapies (9) European consortium for stem cell research (IP) Allogeneic stem cell transplantation (IP) Mesenchymal stem cells for connective tissue disorders (IP) Genome & protein information for immune recognition Stem cells for myocardial repair Dendritic - cells / - Vaccines / - Cancer European Labcourse: therapy (SSA) Post Genomics (6) New approaches for autoimmune diseases (IP) Pharmaceuticals from plants (IP) Antibiotic resistance - Gyrase inhibitors / - Glycopeptides Genomics - Biocatalysis Post-genomics drug discovery

Slide 17

Post Genomics Exploitation of fungal genomics and filamentous fungal biotechnology for human health CA RNA as a human therapeutic tool IP Post-genomics approach to the study of human pathogens NoE Induction of transplant tolerance IP Novel biosafe propagation deficient virus vectors aimed at prevention and treatment of infectious diseases STREP New bioassays and biosensors for detection of harmful microbes STREP FIRST CALL: New approaches for autoimmune diseases (IP) Pharmaceuticals from plants (IP) Antibiotic resistance - Gyrase inhibitors / - Glycopeptides Genomics - Biocatalysis Post-genomics drug discovery SECOND CALL Fungall cell-wall as a target of antifungal therapies STREP Use of RNAi as tool of post-genomic analysis SSA Application of knowledge and technologies in the field of genomics and biotechnology for health

Slide 18

Priority 5 Food Quality and Safety Epidemiology of food related diseases and allergies Epidemiology of food related diseases and allergies Impact of food on health Traceability processes Methods of analysis/detection and control of chemical contaminants and pathogenic microorganisms contaminants and pathogenic microorganisms Safer production methods and healthier foodstuffs Impact of Animal feed on Human Health Environmental health risks Total Food Chain

Slide 19

Slide 20

strategic objectives - nutrition science benefiting from new genomic technologies - virtual centre of excellence - transferring acquired knowledge to stakeholders groups

Slide 21

process of activities Figure 1. The three concentric activities of NuGO

Slide 22

integrating activities

Slide 23

joint research activities

Slide 24

activities to spread excellence Spreading of excellence Activities Training Commercialisation Dissemination Nutrigenomics and society The main NuGO Activities to Spread Excellence

Slide 25

Grain Legumes Integrated Project Grain legumes studied: pea, bean, faba bean, chickpea, lentil and lupin (the legume Medicago truncatula is used as a model system) Proposed budget: Total Costs: 28.153.743 Requested EC Contribution 16.961.701 (50% budget requested by 10 partners) New strategies to improve grain legumes for food and feed : to increase competitiveness of grain legumes in Europe to improve Europes self-sufficiency in plant proteins 66 partners from 19 countries (~80 labs; 9 SMEs): UK; BE; BG; CH; CZ; DE; DK; ES; FR; HU; IL; IT; NL; NO; PL; PT; SE; AU; US

Slide 26

Grain Legumes Integrated Project Genetic & genomic tools food, feed & health Economic & environmental impact Seed composition & quality Crop functioning & seed quality Bioinformatics Coordination & training Dissemination & transfer TTP ~10 SMEs

Slide 27

Cooperation and coordination of national or regional research and innovation activities (i.e. programmes) ERA-NET ERA-NET

Slide 28

Participants: ERA-PG builds on national research programmes in plant genomics (NL, AT, BE, DK, FI FR, DE, IT, NO, SP, UK). Other states may join (BG, EE, GR, HU, IE, PO, PT, RO, SW) Objectives: Improved co-ordinationImproved co-ordination of national plant genomics research programmes Optimising investmentsOptimising investments for plant genomics research and supporting policies Creating long term perspectivesCreating long term perspectives and improved validation of RTD strategies Means: information exchange, web portal, short-term exchange of pgm managers, benchmarking, joint database of experts, position papers ERA-NET co-ordination action in plant genomics (ERA-PG)

Slide 29

Slide 30

A European Strategy for Life Sciences and Biotechnology: The Action Plan - COM (2002) 27 1. Harvesting the Potential The resource Base investing in people generating and exploiting knowledge intellectual property protection capital base Networking Europes Biotechnology Communities A pro-active role for public authorities 3. Responding to global challenge A European agenda for international collaboration Europes responsibilities towards the developing world 2. Governing Life Sciences and Biotechnology Societal scrutiny and dialogue Developing Life Sciences and Biotechnology in harmony with ethical values and social goals Demand-driven applications through informed choice Confidence in science-based regulatory oversight 4. Implementation and coherence across policies, sectors and actors

Slide 31

TECHNOLOGY PLATFORMS European Council in March 2003 ...European Research and Innovation Area to be strengthened to the benefit of all in the enlarged EU by creating European technology platforms bringing together technological know-how, industry, regulators and financial institutions to develop a strategic agenda for leading technologies, in areas such as plant genomics Technology Platforms have been identified as important elements for increasing competitiveness in the Communication Industrial policy in an enlarged Europe (Dec. 2002) and the 3% action plan (April 2003)

Slide 32

3% Action Plan: better use of public financing to increase leverage effect on private investment; R&D in corporate strategies and management. Progress jointly (open process of co-ordination; European technology platforms) Improve public support to research and innovation (human resources; academia-industry links; mix of public financing instruments;..); Redirect public spending towards research and innovation (refocus public spending; state aid rules; public procurement;...)

Slide 33

Slide 34

Plant Genomics SHARED PLATFORM EPSO Industry Farmers cooperatives Biotech entrepreneurs Consumer groups Environmental NGO Policy DGs

Slide 35

Improving the diagnostic and therapeutic arsenal for health care LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH

Slide 36

TOWARDS JOINT INDUSTRIAL PROJECTS Treaty on the European Union Treaty on the European Union Article 171 The Community may set up joint undertakings or any other structure necessary for the efficient execution of Community research, technological development and demonstration programmes E.g. GALILEO Joint Undertaking Members are EC, ESA, EIB, private enterprises. A tendering process is foreseen. Encompasses R&D, validation of developments, demonstration, coordination with national activities. Mio 5.0 to be subscribed by entrerprises, down to 250 000 for SMEs

Slide 37

European Research Council Joint Industrial Projects